Compare Manhattan Associates Inc (MANH) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

MANH trades at $222.71, up 2.21% today, near its pivot point of $222. The stock shows strong technical momentum with a bullish moving average signal. Fundamentally, the company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.39 exceeding the $1.32 estimate. High profitability is evident with a net margin of 18.67% and ROE of 96.38%, though valuation multiples like a P/E of 63.07 are elevated. Recent news includes a product launch of 'Editions' for scalable solutions but also ongoing legal investigations into fiduciary duties.

The outlook is mixed; strong earnings momentum and analyst consensus (80% buy ratings) support upside toward the $260 high target, but high valuation and legal overhang pose risks. The stock's current level near resistance at $226 requires monitoring for a breakout or pullback. Key catalysts include Q3 2026 earnings and resolution of the legal scrutiny.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.